Adverse event
France pauses chikungunya vaccinations in the elderly after patient death
Vaccines, Chikungunya Fever, Elderly (population group), Adverse event, France, Latex Fixation Tests, Reunion Island, Disease Outbreaks, Age, older, Vaccination
Distinguishing Adverse Events from Complications in Heart Attacks
heart attack, adverse event, complication, cardiac health, medical emergency
Dyne Therapeutics Faces Setbacks Despite Promising DMD Study Results
Dyne Therapeutics, Duchenne Muscular Dystrophy (DMD), DELIVER trial, DYNE-251, adverse events, executive departures
Merck Acquires Curon’s Bispecific Antibody in $1.3B Deal; Legend Biotech Evaluates Options Amid Probes; Amgen’s FDA Filing Reveals Missing Adverse Events
Merck, Curon Biopharmaceutical , Bispecific antibody, Legend Biotech, Amgen, FDA filing, Adverse events, China investigations, CAR-T therapy, Carvykti
FDA Approval of Amgen’s Imdelltra for Lung Cancer Amidst Challenges and Market Competition
Amgen, Imdelltra, FDA approval, lung cancer, bispecific T-cell engager, adverse events, Merck, Curon, Legend Biotech
Verve Temporarily Halts Lead Base Editing Study Following Adverse Event, Prioritizes Alternative Therapy
Verve Therapeutics, Lead base editing program, Adverse event, VERVE-101, Serious adverse events (SAEs), Grade 3 ALT elevation, Thrombocytopenia, Pause enrollment in Heart-1 study, Alternative therapy focus: VERVE-102, Ionizable lipid delivery system, Phase Ib Heart-2 clinical trial, Q2 2024 initiation of Heart-2 clinical trial.